Low-dose Evaluation of Aspirin After STEMI Patients With PCI: A Multicenter, Double-blind, Randomized Controlled Clinical Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3612 participants.

Also called NCT06756945

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,612 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06756945
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06756945. Randomized; double masking; primary purpose treatment. Start 2025-01 (anticipated); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Low-dose Evaluation of Aspirin After STEMI Patients With PCI: A Multicenter, Double-blind, Randomized Controlled Clinical Trial
Acronym
LEAST
Condition
ST-elevation Myocardial Infarction (STEMI)
Intervention (Drug)
aspirin 50 mg once daily (one 50 mg aspirin tablet plus one matching placebo tablet) plus ticagrelor 90 mg twice daily
Intervention (Drug)
aspirin 100 mg once daily (two 50 mg aspirin tablets) plus ticagrelor 90 mg twice daily
Lead sponsor
Beijing Anzhen Hospital (class: other)

Record details

Record id
cardio:ct-nct06756945
Content hash
dd3db925d50d16a70ca5d1d8356fa8e3b0b028af49561ee9b154b6c8a35a4f42